Co-Diagnostics, Inc. logo CODX - Co-Diagnostics, Inc.

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY
0
BUY 2
HOLD 3
SELL 0
STRONG
SELL
0
| PRICE TARGET: $180.00 DETAILS
HIGH: $180.00
LOW: $180.00
MEDIAN: $180.00
CONSENSUS: $180.00
UPSIDE: 1470.56%

About Co-Diagnostics, Inc. (https://co-dx.com)

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.

Key Executives

NAME TITLE DOB SALARY
Dwight H. Egan Chairman, CEO & President 1953 $460,000 USD
Brian L. Brown Chief Financial Officer & Company Secretary 1976 $365,000 USD
Richard David Abbott President 1972 $305,000 USD
Andrew Benson Head of Investor Relations
Christopher Thurston Chief Technology Officer
Dan Bohrer Vice President of Finance & Accounting
David Nielsen Chief Operating Officer
Mayuranki Almaula Senior Vice President of Overseas Operations & Strategic Alliances
Seth Egan Chief Commercialization Officer

Company Peers

Peer analysis pending, check back in 1-2 minutes.